文献速递临床试验与 GCP基础与转化研究

三联合广谱中和单克隆抗体治疗HIV-1的安全性与抗病毒活性:一项1期临床试验

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
PubMed 文献 · Nat Med · 2022-05-12

该研究分两部分:第一部分为单中心、随机、双盲、剂量递增、安慰剂对照的首次人体试验,在24名无HIV成人中评估PGDM1400单用或联合PGT121;第二部分为多中心、开放标签试验,在5名未接受抗逆转录病毒治疗的HIV感染者中评估PGDM1400、PGT121与VRC07-523LS三联组合。结果显示静脉给药安全耐受,三联组合可使血浆HIV RNA最大平均下降2.04 log10拷贝/ml,但所有参与者在中位20天后出现病毒反弹。

要点

  • PGDM1400单用或联合PGT121在无HIV成人中安全耐受,剂量递增至30 mg/kg。
  • 三联抗体组合使未治疗HIV感染者血浆HIV RNA最大平均下降2.04 log10拷贝/ml。
  • 所有参与者在中位20天后病毒反弹,反弹病毒对PGDM1400和PGT121部分至完全耐药。

核心结论

  • 数据提示未来广谱中和抗体组合可能需要实现广谱抗病毒活性并维持高血清浓度才能介导病毒控制。

研究设计与样本

  • 第一部分为单中心、随机、双盲、剂量递增、安慰剂对照的首次人体试验,纳入24名无HIV成人,评估PGDM1400单用或联合PGT121。
  • 第二部分为多中心、开放标签试验,纳入5名未接受抗逆转录病毒治疗的HIV感染者,评估PGDM1400、PGT121与VRC07-523LS三联组合。
  • 主要终点为两部分的安全性和耐受性、药代动力学,以及第二部分中未接受抗逆转录病毒治疗的HIV感染者的抗病毒活性;次要终点为第二部分CD4+ T细胞计数变化及与PGDM1400、PGT121和VRC07-523LS耐药相关的HIV-1序列变异。

主要发现

  • 静脉给予PGDM1400在剂量高达30 mg/kg时安全且耐受良好,与PGT121和VRC07-523LS联用时亦安全耐受。
  • 单次静脉输注三种抗体各20 mg/kg使病毒血症个体血浆HIV RNA最大平均下降2.04 log10拷贝/ml。
  • 所有参与者在中位20天后出现病毒反弹,尽管平均VRC07-523LS血清浓度为93 µg/ml。
  • 反弹病毒在体外对PGDM1400和PGT121显示部分至完全耐药,而对VRC07-523LS的敏感性得以保留。
  • 试验达到预设终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral escape, indicating that at least a triple bNAb therapy may be needed for robust suppression of viremia. We performed a two-part study consisting of a single-center, randomized, double-blind, dose-escalation, placebo-controlled first-in-human trial of the HIV-1 V2-glycan-specific antibody PGDM1400 alone or in combination with the V3-glycan-specific antibody PGT121 in 24 adults without HIV in part 1, as well as a multi-center, open-label trial of the combination of PGDM1400, PGT121 and the CD4-binding-site antibody VRC07-523LS in five viremic adults living with HIV not on antiretroviral therapy (ART) in part 2 ( NCT03205917 ). The primary endpoints were safety, tolerability and pharmacokinetics for both parts and antiviral activity among viremic adults living with HIV and not on ART for part 2 of the study. The secondary endpoints were changes in CD4+ T cell counts and development of HIV-1 sequence variations associated with PGDM1400, PGT121 and VRC07-523LS resistance in part 2. Intravenously administered PGDM1400 was safe and well-tolerated at doses up to 30 mg kg-1 and when given in combination with PGT121 and VRC07-523LS. A single intravenous infusion of 20 mg kg-1 of each of the three antibodies reduced plasma HIV RNA levels in viremic individuals by a maximum mean of 2.04 log10 copies per ml; however, viral rebound occurred in all participants within a median of 20 days after nadir. Rebound viruses demonstrated partial to complete resistance to PGDM1400 and PGT121 in vitro, whereas susceptibility to VRC07-523LS was preserved. Viral rebound occurred despite mean VRC07-523LS serum concentrations of 93 µg ml-1. The trial met the pre-specified endpoints. Our data suggest that future bNAb combinations likely need to achieve broad antiviral activity, while also maintaining high serum concentrations, to mediate viral control.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Julg B, Stephenson KE, Wagh K, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022. PMID: 35551291. doi:10.1038/s41591-022-01815-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。